Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia
The purpose of this study is to evaluate the efficacy and safety of Thalidomide in patients with leukemia.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||UARK, 98-032, Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia|
- To evaluate the efficacy and safety of Thalidomide in patients with leukemia.
|Study Start Date:||August 1998|
|Estimated Study Completion Date:||May 2005|
Patients will take Thalidomide tablets at bedtime daily until remission. The dose will be increased gradually and modified according to side-effects. The drug will be given daily up to the time of complete remission then as long as it is beneficial.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00083694
|United States, Arkansas|
|University of Arkansas for Medical Sciences/MIRT|
|Little Rock, Arkansas, United States, 72205|
|Principal Investigator:||Barthel Barlogie, M.D., Ph.D.||UAMS|